Compare BLBD & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | CRVS |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2013 | 2016 |
| Metric | BLBD | CRVS |
|---|---|---|
| Price | $54.82 | $15.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $67.20 | $28.00 |
| AVG Volume (30 Days) | 470.0K | ★ 1.1M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.78 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $1,480,099,000.00 | N/A |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | $60.12 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $30.15 | $2.54 |
| 52 Week High | $62.90 | $26.95 |
| Indicator | BLBD | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 41.19 |
| Support Level | $54.23 | $6.65 |
| Resistance Level | $58.57 | $18.73 |
| Average True Range (ATR) | 2.52 | 1.02 |
| MACD | -0.81 | -0.48 |
| Stochastic Oscillator | 8.18 | 11.94 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).